This suggests that the beneficial inhibitory effects of GLP-1R agonists on the occurrence and progression of cardiovascular diseases and the mechanism may not entirely dependent on the treatment of T2DM; therefore, our study included patients with CHD or not confirmed by coronary angiography and compared the distribution of macrophages and their surface GLP-1R without bias caused by the difference in T2DM distribution or GHbA1c level between the two groups. The gene discussed is GLP1R; the disease is cardiovascular disorder.